Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin-Reference-Cited by-同舟云学术

Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin

Published:2023-05-12 Issue:6 Volume: Page:234-240
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Petunina N. A.¹^ORCID,Goncharova E. V.¹^ORCID,Теlnova M. Е.¹^ORCID,Kuzina I. A.¹^ORCID,Martirosyan N. S.¹^ORCID,Sochneva A. Yu.¹^ORCID

Affiliation:

1. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

Diabetes mellitus, a well-known risk of cardiovascular disease (CVD), in patients with type 2 diabetes mellitus (DM2) Hyperglycemia has been found to be an increased risk of coronary heart disease and mortality. In real clinical practice, physicians are faced with the problem of choice when prescribing new hypoglycemic drugs in patients with type 2 diabetes and high cardiovascular risk. Modern possibilities and approaches to the treatment of DM2 have contributed to the creation of a promising class of hypoglycemic drugs that block renal glucose reabsorption - inhibitors of the sodium-glucose cotransporter type 2 (iSGLT-2). The unique mechanism of SGLT2 inhibition not only improves glycemic control, but also has cardio- and nephroprotective effects in patients with DM2 and at high cardiovascular risk. According to current recommendations, when choosing the tactics of treating patients with DM2 and the presence of risk factors for cardiovascular diseases or confirmed atherosclerotic cardiovascular diseases, preference is given to GLP-1 and/or iSGLT-2 receptor agonists in combination with the first-line drug, metformin. This article presents the main results of the efficacy and safety of ertugliflozin in a number of clinical studies and its beneficial effect not only on glycemic control, but also on cardio- and nephroprotective effects. The article also reflects the key results of an extensive program of randomized clinical trials VERTIS (acronym for eValuation of ERTugliflozinefficacy and Safety; evaluation of the efficacy and safety of ertugliflozin): including patients with type 2 diabetes and established atherosclerotic cardiovascular disease (VERTIS CV), with type 2 diabetes and CKD 3rd stage (VERTIS RENAL), as well as VERTIS MONO, VERTIS MET, VERTIS SITA, VERTIS SU and VERTIS FACTORIAL.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference31 articles.

1. Bommer C., Heesemann E., Sagalova V., Manne-Goehler J., Atun R., Bärnighausen T. et al. The Global Economic burden of Diabetes in Adults Aged 20–79 Years: a Cost-Of-Illness Study. Lancet Diabetes Endocrinol. 2017;5(6):423–430. https://doi.org/10.1016/s2213-8587(17)30097-9.

2. Chatterjee S., Khunti K., Davies M. J. Type 2 Diabetes. Lancet. 2017;389(10085):2239–2251. https://doi.org/10.1016/S0140-6736(17)30058-2.

3. Cosentino F., Grant P.J., Aboyans V., Bailey C. J., Ceriello A., Delgado V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323. https://doi.org/10.1093/eurheartj/ehz486.

4. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;(157):107843. https://doi.org/10.1016/j.diabres.2019.107843.

5. Eknoyan G., Lameire N., Wheeler D.C., Jadoul M., Winkelmayer W.C., Arici M et al. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. https://doi.org/10.1016/j.kint.2020.06.019.